Orion Oyj (0M2O) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Orion Oyj €70.58, price €80.65, upside -12.5%, quality 82 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Orion Oyj for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range €29.20 – €84.05 · fair‑value band €52.55 – €88.62 · the €80.65 price screens above the €70.58 fair value. Dashed = 300-day average. As of Sep 23, 2026.
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally.
Show more
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychotic; Trexan for rheumatoid arthritis and cancer; Easyhaler product portfolio for asthma and COPD; and Dexdor, Precedex, and Dexmedetomidine products for human use. The company also provides Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, it offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells drugs and products manufactured by other companies. Additionally, the company provides self-care products, including non-prescription medicines, cosmetics, dietary supplements, vitamins, and skincare products. It also offers its products online. The company has a licensing agreement with Tenax Therapeutics, Inc. to develop oral levosimendan (TNX-103) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF); and Bayer for the development and commercialisation of darolutamide Nubeqa. Orion Oyj was founded in 1917 and is headquartered in Espo, Finland.
Stock analysis
Orion Oyj (0M2O) currently trades at €80.65, while our model-based Fair Value estimate is €70.58, 12.5% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of €77.90 per share, and 2 of the 23 models we run sit above the €80.65 price.
Bear case: the Asset-Based group reads lowest at €7.95, and 21 of the 23 models stay below the price. Evidence for this calculation is low.
Scenario range: €52.55 (bear) to €88.62 (bull), the price of €80.65 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 82/100 (high quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Orion Oyj reported revenue of €1.1B in FY2020 versus €1.1B in FY2016, a compound +0.1%/yr. Reported net income was €220M in FY2020, compounding −3.1%/yr from FY2016.
Key figures
Market cap €5.0B · P/S ratio 2.42 · Dividend yield 2.2% · Net margin 20.4% · Return on equity 53.7% · Return on assets (EBIT) 25.6% · Operating margin 33.8% · Revenue (TTM) €2.1B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 58 out of 100 (medium confidence).
What moves the price
The share trades about 4% below its 52-week high and 42% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −12%, 0M2O screens richer than that median.
Fair Value models
Bear €52.55Fair Value €70.58Bull €88.62
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+2.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.4%
’16
’17
’18
’19
’20
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
29.3% (2016) → 26.0% (2020)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 73 stocks
Beats the industry median on 11/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score82 · Top 25%
Fair Value upside−9.7% · Above median
Profitability
Return on equity (TTM)53.7% · Top 25%
Return on assets26.3% · Top 25%
Net margin (TTM)28.5% · Top 25%
Operating margin (TTM)33.8% · Top 25%
Growth and dividend
Revenue growth25.2% · Top 25%
Dividend yield (TTM)2.2% · Above median
Balance sheet
Debt / equity0.14× · Below median
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Orion Oyj Fair Value". https://www.fairvalue-calculator.com/stock/0M2O
Frequently asked questions
Is Orion Oyj (0M2O) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of €70.58 versus a price of €80.65, about −12% upside (overvalued).
What is the fair value of 0M2O?
Our model-based fair value for Orion Oyj is €70.58 (as of Sep 23, 2026), built from audited fundamentals. The current price: €80.65.
What is the quality score of 0M2O?
Orion Oyj has a Quality Score of 82/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Orion Oyj (0M2O)?
Our model-based price target is the fair value of €70.58 (as of Sep 23, 2026) from 23 valuation models. Cautious scenario €52.55, optimistic scenario €88.62. It is a calculation from audited fundamentals, not an analyst target.
What is the Orion Oyj stock forecast for 2026?
Our models put fair value at €70.58, about −12% upside versus a price of €80.65 (overvalued). Cautious scenario €52.55, optimistic scenario €88.62. The calculation is refreshed regularly with new filings.
What is the revenue of Orion Oyj (0M2O)?
Orion Oyj reported trailing-twelve-month revenue of about €2.1B (latest available figure, as of Sep 23, 2026).
Does Orion Oyj pay a dividend?
Orion Oyj currently shows a dividend yield of about 2.23% relative to its recent price (as of Sep 23, 2026).
What is the intrinsic value of Orion Oyj (0M2O)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Orion Oyj it is €70.58 per share (as of Sep 23, 2026), against a price of €80.65. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Orion Oyj stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 0M2O trades above its calculated fair value: price €80.65, fair value €70.58, a gap of about −12% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0M2O?
No. The price is what the market pays today (€80.65); the fair value is what the company's own numbers justify (€70.58). For Orion Oyj the two are €10.07 per share apart. That gap is exactly why we show both numbers side by side.
How much is Orion Oyj worth?
The market values Orion Oyj at about €5.0B (market capitalisation, as of Sep 23, 2026). Per share that is €80.65; our models calculate a fair value of €70.58 per share.
What do the bullish and bearish scenarios say about 0M2O?
Our models span a range for Orion Oyj: cautious scenario €52.55, base €70.58, optimistic €88.62 per share (as of Sep 23, 2026, price €80.65). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Orion Oyj (0M2O)?
Balance-sheet figures for Orion Oyj (as of Sep 23, 2026): return on equity 53.7%, debt of 0.14 per unit of equity. They feed the Quality Score of 82/100, which measures business quality independently of the share price.
How far is 0M2O from its 52-week high?
Orion Oyj trades at €80.65, about 4% below its 52-week high of €84.05 and 42% above the low of €56.70 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €70.58 is for.
Which stocks are comparable to Orion Oyj?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Orion Oyj stock attractive at the current price?
The data as of Sep 23, 2026: price €80.65, calculated fair value €70.58 (−12%), Quality Score 82/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0M2O calculated?
We run Orion Oyj through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €70.58, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Orion Oyj itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Orion Oyj (0M2O)?
The closing price on Oct 2, 2026 was €80.65. Our model-based fair value is €70.58, about −12% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Orion Oyj right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Orion Oyj
How large is the market capitalisation of Orion Oyj (0M2O)?
The market capitalisation of Orion Oyj is €5.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Orion Oyj (0M2O)?
The price-to-sales ratio of Orion Oyj is 2.42 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Orion Oyj (0M2O)?
The dividend yield of Orion Oyj is 2.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Orion Oyj (0M2O)?
The net margin of Orion Oyj is 20.4% (fiscal year 2020). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Orion Oyj (0M2O)?
The return on equity (ROE) of Orion Oyj is 53.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Orion Oyj (0M2O)?
On an EBIT basis the return on assets of Orion Oyj is 25.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Orion Oyj (0M2O)?
The operating margin of Orion Oyj is 33.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Orion Oyj (0M2O)?
Revenue at Orion Oyj is growing +25.2% versus a year earlier (3y avg +1.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Orion Oyj (0M2O)?
Earnings per share at Orion Oyj are growing +69.5% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Orion Oyj in the live analysis
One click puts Orion Oyj on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
